Grazax in children

Grazax, the grass-pollen allergen tablet from ALK-Abello, has had its licence extended to include use in children and adolescents aged five to 17 years.

The fast-melting sublingual tablet for once-daily administration is indicated for the treatment of grass pollen-induced rhinitis and conjunctivitis.

Grazax is non-injection immunotherapy and the first dose should be given under medical supervision.

View Grazax drug record

Further information: ALK-Abello

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in